Literature DB >> 9698727

Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors.

A Hilbig1, L M Barbosa-Coutinho.   

Abstract

The authors assessed 116 cases of meningiomas classified as typical, atypical and anaplastic and they used an immunohistochemical technique for estrogen and progesterone receptors attempting to determine if there is any difference between typical and non-typical tumors in relation to hormone receptors. The immunohistochemical technique to estrogen receptors was negative in all meningiomas studied. Progesterone receptors were detected in 58.3% of typical, and in 48.2% of non-typical meningiomas. This difference was not statistically significant. However, individually considering the criteria used for selection of non-typical tumours, those that concurrently displayed brain invasion and increased mitotic activity or necrosis, as well as the summation of those three features, were predominantly negative for progesterone receptors (respectively p = 0.038; p = 0.001; and p = 0.044). The authors conclude that estrogen receptors were not present in meningiomas; that progresterone receptors in isolation are not enough to predict a higher tumoral malignancy but can be useful associated with other histological features.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698727     DOI: 10.1590/s0004-282x1998000200005

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  9 in total

Review 1.  Possible effects of progesterone on human central nervous system and neurogenic tumors.

Authors:  T Inoue; H Sasano
Journal:  J Endocrinol Invest       Date:  2004-01       Impact factor: 4.256

2.  Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.

Authors:  Camila Batista de Oliveira Silva; Bárbara Roberta Ongaratti; Geraldine Trott; Taiana Haag; Nelson Pires Ferreira; Carolina Garcia Soares Leães; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Expression of Progesterone Receptor and Its Association with Clinicopathological Characteristics in Meningiomas: A Cross-Sectional Study.

Authors:  Leah Mnango; Angela Mwakimonga; Advera I Ngaiza; James J Yahaya; Edda Vuhahula; Amos R Mwakigonja
Journal:  World Neurosurg X       Date:  2021-07-14

4.  Pituitary adenoma associated with intraventricular meningioma: case report.

Authors:  Leodante B da Costa; Jay Riva-Cambrin; Asheesh Tandon; Michael Tymianski
Journal:  Skull Base       Date:  2007-09

5.  Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.

Authors:  Stefan Wolfsberger; Soroush Doostkam; Hans-Gerd Boecher-Schwarz; Karl Roessler; Michael van Trotsenburg; Johannes A Hainfellner; Engelbert Knosp
Journal:  Neurosurg Rev       Date:  2004-05-27       Impact factor: 3.042

6.  Rhabdoid meningioma: clinical features and MR imaging findings in 15 patients.

Authors:  E Y Kim; Y C Weon; S T Kim; H-J Kim; H S Byun; J-I Lee; J H Kim
Journal:  AJNR Am J Neuroradiol       Date:  2007-09       Impact factor: 3.825

7.  Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence.

Authors:  G Trott; J F S Pereira-Lima; C G S Leães; N P Ferreira; L M Barbosa-Coutinho; M C Oliveira
Journal:  Braz J Med Biol Res       Date:  2015-03-03       Impact factor: 2.590

Review 8.  Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Authors:  Tamás Deli; Mónika Orosz; Attila Jakab
Journal:  Pathol Oncol Res       Date:  2019-01-08       Impact factor: 3.201

9.  Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression.

Authors:  Madhumita Mukhopadhyay; Chhanda Das; Madhu Kumari; Ankita Sen; Bedabrata Mukhopadhyay; Biswanath Mukhopadhyay
Journal:  J Lab Physicians       Date:  2017 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.